Related Experiment Video
Updated: Dec 12, 2025
Derivation of Glial Restricted Precursors from E13 mice
Published on: June 20, 2012
Transplanted Oligodendrocyte Progenitor Cells Survive in the Brain of a Rat Neonatal White Matter Injury Model but
Shino Ogawa1,2, Mutsumi Hagiwara1, Sachiyo Misumi1
1Departments of Neurophysiology and Brain Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Insights
Insulin-like growth factor 2 (IGF2) promotes oligodendrocyte progenitor cell (OPC) differentiation in neonatal white matter injury (WMI) models. However, OPC transplantation shows limited success due to inhibited differentiation in the brain.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Developmental Biology
Background:
- Neonatal white matter injury (WMI) from hypoxia-ischemia poses significant risks to preterm infants.
- Oligodendrocyte progenitor cells (OPCs) are particularly vulnerable in neonatal WMI.
- Cell-based therapies offer potential for WMI treatment by providing trophic support and cell replacement.
Purpose of the Study:
- To investigate the trophic effects of insulin-like growth factor 2 (IGF2) on OPCs.
- To evaluate OPC transplantation as a cell replacement therapy for neonatal WMI.
- To explore the role of IGF2 in OPC differentiation and survival in a rat model.
Main Methods:
- Utilized a rat model of neonatal WMI.
- Confirmed enhanced Igf2 mRNA expression in affected brain regions.
- Performed in vitro studies assessing IGF2's effect on OPC differentiation.
- Transplanted GFP-labeled OPCs into the corpus callosum of WMI model rats.
- Monitored grafted cell survival and differentiation for 8 weeks.
Main Results:
- IGF2 was confirmed to promote OPC differentiation into mature oligodendrocytes in vitro.
- IGF2 and its receptor IGF2R showed co-expression in relevant brain cells, suggesting autocrine/paracrine signaling.
- Transplanted OPCs survived for 8 weeks, but the number of mature oligodendrocytes remained low compared to controls.
- These findings indicate an inhibitory mechanism against differentiation in the WMI brain environment.
Conclusions:
- IGF2 provides trophic support and promotes OPC differentiation, a key factor in neonatal WMI.
- Cell replacement therapy for neonatal WMI requires addressing brain mechanisms that inhibit oligodendrocyte differentiation.
- Further research is needed to overcome differentiation barriers for successful cell-based therapies in neonatal WMI.
Abstract:
Preterm infants have a high risk of neonatal white matter injury (WMI) caused by hypoxia-ischemia. Cell-based therapies are promising strategies for neonatal WMI by providing trophic substances and replacing lost cells. Using a rat model of neonatal WMI in which oligodendrocyte progenitors (OPCs) are predominantly damaged, we investigated whether insulin-like growth factor 2 (IGF2) has trophic effects on OPCs in vitro and whether OPC transplantation has potential as a cell replacement therapy. Enhanced expression of Igf2 mRNA was first confirmed in the brain of P5 model rats by real-time polymerase chain reaction. Immunostaining for IGF2 and its receptor IGF2 R revealed that both proteins were co-expressed in OLIG2-positive and GFAP-positive cells in the corpus callosum (CC), indicating autocrine and paracrine effects of IGF2. To investigate the in vitro effect of IGF2 on OPCs, IGF2 (100 ng/ml) was added to the differentiation medium containing ciliary neurotrophic factor (10 ng/ml) and triiodothyronine (20 ng/ml), and IGF2 promoted the differentiation of OPCs into mature oligodendrocytes. We next transplanted rat-derived OPCs that express green fluorescent protein into the CC of neonatal WMI model rats without immunosuppression and investigated the survival of grafted cells for 8 weeks. Although many OPCs survived for at least 8 weeks, the number of mature oligodendrocytes was unexpectedly small in the CC of the model compared with that in the sham-operated control. These findings suggest that the mechanism in the brain that inhibits differentiation should be solved in cell replacement therapy for neonatal WMI as same as trophic support from IGF2.
